Global safety of Coxibs and NSAIDs

Current Topics in Medicinal Chemistry

Volumn 5, Issue 5, 2005, Pages 465-473

  Pham, Kevin ^a   Hirschberg, Raimund ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Cardiovascular safety; Cox 2 inhibitor; Coxib; Drug safety; Gastrointestinal safety; NSAID; Renal safety

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CAPTOPRIL; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUPROFEN; LANSOPRAZOLE; LOSARTAN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ACUTE KIDNEY FAILURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG SAFETY; EDEMA; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERKALEMIA; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; NEPHROTIC SYNDROME; OSTEOARTHRITIS; PAIN; PEPTIC ULCER; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SODIUM RETENTION; STOMACH OBSTRUCTION; STOMACH PERFORATION; STOMACH ULCER; THROMBOGENICITY; UPPER GASTROINTESTINAL BLEEDING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY DISEASES; RISK;

EID: 22144481673     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054201640     Document Type: Review

References (77)

1. Wolfe, M.M., Lichtenstein, D.R., Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1999, 340, 1888-1899.
2. Hernandez-Diaz, S., Rodriguez, L.A. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation, an overview of epidemiologic studies published in the 1990s. Arch. Intern. Med. 2000, 160, 2093-2099.
3. Hernandez-Diaz S., Garcia-Rodriguez, L.A. Epidemiologic assessment of the safety of conventional nonsteroidal antiinflammatory drugs. Am. J. Med. 2001, 110 (Suppl. 3A), 20S-27S.
4. Griffin, M.R., Yared, A., Ray, W.A. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. Am. J. Epidemiol. 2000, 151, 488-496.
5. Smith, W.L, DeWitt, D.L. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Semin. Nephrol. 1995, 15, 179-194.
6. Xie, W.L., Chipman, J.G., Robertson, D.L., Erikson, R.L., Simmons, D.L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA 1991, 88, 2692-2696.
7. O'Banion, M.K., Sadowski, H.B., Winn, V., Young, D.A. A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J. Biol. Chem. 1991, 266, 23261-23267.
8. Kujubu, D.A., Fletcher BS, Varnum B.C., Lim R.W., Herschman, H.R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 1991, 266, 12866-12872.
9. Crofford, L.J. COX-1 and COX-2 tissue expression, implications and predictions. J. Rheumatol. 1997, 24 (Suppl. 49), 15-19.
10. McMurray, R.W., Hardy, K.J. Cox-2 inhibitors, today and tomorrow. Am. J. Med. Sci. 2002, 323, 181-189.
11. Meade E.A., Smith, W.L., DeWitt, D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1993, 268, 6610-6614.
12. Kaufman, D.W., Kelly, J.P., Wiholm, B.E., Laszlo, A., Sheehan, J.E., Koff, R.S., Shapiro, S, The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am. J. Gastroenterol. 1999, 94, 3189-3196.
13. Garcia Rodriguez, L.A, Hernandez-Diaz, S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiol. 2001, 12, 570-576.
14. Weil, J., Colin-Jones, D., Langman, M,. Lawson, D., Logan R, Murphy M, Rawlins M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995, 310, 827-830.
15. Cryer, B., Feldman, M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterol. 1999, 117, 17-25.
16. Ivey, K.J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Actions of therapeutic agents. Am. J. Med. 1988, 84, 41-48.
17. Sorensen, H.T., Mellemkjaer, L., Blot, W.J, Nielsen, G.L, Steffensen, F.H, McLaughlin, J.K., Olsen, J.H. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am. J. Gastroenterol. 2000, 95, 2218-2224.
18. Goldstein, J.L., Silverstein, F.E., Agrawal, N.M., Hubbard, R.C., Kaiser, J., Maurath, C.J., Verburg, K.M., et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am. J. Gastroenterol. 2000, 95, 1681-1690.
19. Silverstein, F.E, Faich, G., Goldstein, J.L, Simon, L.S, Pincus, T., Whelton, A., Makuch, R., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis, the CLASS study, A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284, 1247-1255.
20. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000, 343, 1520-1528.
21. Pavelka, K., Recker, D.P., Verburg, K.M. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers, results of a 26-week trial. Rheumatol. (Oxford) 2003, 42, 1207-1215.
22. Garcia Rodriguez, L.A., Cattaruzzi, C., Troncon, M.G., Agostinis, L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch. Intern. Med. 1998, 158, 33-39.
23. Blower, A.L., Brooks, A., Fenn, G.C., Hill, A., Pearce, M.Y., Morant, S., Bardhan, K.D. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment. Pharmacol. Ther. 1997, 11, 283-291.
24. Gutthann, S.P., Garcia, Rodriguez, L.A., Raiford, D.S. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiol. 1997, 8, 18-24.
25. Jick, S.S., Perera, D.R., Walker, A.M., Jick, H. Non-steroidal antiinflammatory drugs and hospital admission for perforated peptic ulcer. Lancet 1987, 2, 380-382.
26. Katschinski, B.D., Logan, R.F., Davies, J., Langman, M.J. Audit of mortality in upper gastrointestinal bleeding. Postgrad. Med. J. 1989, 65, 913-917.
27. Savage, R.L., Moller, P.W., Ballantyne, C.L., Wells, J.E. Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapy. Arthritis Rheum. 1993, 36, 84-90.
28. Voskuyl, A.E., Van de Laar, M.A., Moens, H.J., Van der Korst, J.K. Extra-articular manifestations of rheumatoid arthritis, risk factors for serious gastrointestinal events. Ann. Rheum. Dis. 1993, 52, 771-775.
29. Lai, K.C., Lam, S.K., Chu, K.M., Wong, B.C., Hui, W.M., Hu, W.H., Lau, G.K., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. 2002, 346, 2033-2038.
30. Catella-Lawson, F., Crofford, L.J. Cyclooxygenase inhibition and thrombogenicity. Am. J. Med. 2001, 110 (Suppl. 3A), 28S-32S.
31. Collaborative overview of randomised trials of antiplatelet therapy-I, Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Anti-platelet Trialists' Collaboration. BMJ 1994, 308, 81-106.
32. Patrono, C., Coller, B., Dalen, J.E., Fuster, V., Gent, M., Harker, L.A., Hirsh, J. et al. Platelet-active drugs, the relationships among dose, effectiveness, and side effects. Chest 1998, 114, 470S-488S.
33. Brochier, M.L. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. Eur. Heart J. 1993, 14, 951-957.
34. Fornaro, G., Rossi, P., Mantica, P.G., Caccia, M.E., Aralda, D., Lavezzari, M., Pamparana, F., et al. Indobufen in the prevention of thromboembolic complications in patients with heart disease. A randomized, placebo-controlled, double-blind study. Circulation 1993, 87, 162-164.
35. Mukherjee, D., Nissen, S.E., Topol, E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286, 954-959.
36. Wallberg-Jonsson, S., Johansson, H., Ohman, M.L., Rantapaa-Dahlqvist, S. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J. Rheumatol. 1999, 26, 2562-2571.
37. Wolfe, F., Mitchell, D.M., Sibley, J.T., Fries, J.F., Bloch, D.A., Williams, C.A., Spitz, P.W. et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994, 37, 481-494.
38. Konstam, M.A., Weir, M.R., Reicin, A., Shapiro, D., Sperling, R.S., Barr, E., Gertz, B.J. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104, 2280-2288.
39. Reicin, A.S., Shapiro, D., Sperling, R.S., Barr, E., Yu, Q. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am. J. Cardiol. 2002, 89, 204-209.
40. Watson, D.J., Rhodes, T., Cai, B., Guess, H.A. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. 2002, 162, 1105-1110.
41. Rahme, E., Pilote, L., LeLorier, J. Association between naproxen use and protection against acute myocardial infarction. Arch. Intern. Med. 2002, 162, 1111-1115.
42. Solomon, D.H., Glynn, R.J., Levin, R., Avorn, J. Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch. Intern. Med. 2002, 162, 1099-1104.
43. Farkouh, M.E., Kirshner, H., Harrington, R.A., Ruland, S., Verheugt, F.W., Schnitzer, T.J., Burmester, G.R., Mysler, E., Hochberg, M.C., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Gimona, A., Matchaba, P., Hawkey, C.J., Chesebbro, J.H. TARGET Study Group, Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364, 675-684.
44. Schnitzer, T.J., Burmester, G.R., Mysler, E., Hochberg, M.C., Doherty, M. Related Articles, Linkes Ehrsam, E., gitton, X., Krammer, G., Mellein, B., Matchaba, P., Gimona, A. Hawkey, G.J. TARET STudy Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004, 364, 665-674.
45. Brater, D.C., Harris, C., Redfern, J.S., Gertz, B.J. Renal effects of COX-2-selective inhibitors. Am. J. Nephrol. 2001, 21, 1-15.
46. Harris, R.C. Jr. Cyclooxygenase-2 inhibition and renal physiology. Am. J. Cardiol. 2002, 89, 10D-17D.
47. Harris, R.C., Breyer, M.D. Physiological regulation of cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal. Physiol. 2001, 281, F1-11.
48. Guan, Y., Chang, M., Cho, W., Zhang, Y., Redha, R., Davis, L., Chang, S. et al. Cloning, expression, and regulation of rabbit cyclooxygenase-2 in renal medullary interstitial cells. Am. J. Physiol. 1997, 273, F18-26.
49. Harris, R.C., McKanna, J.A., Akai, Y., Jacobson, H.R., Dubois, R.N., Breyer, M.D. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J. Clin. Invest. 1994, 94, 2504-2510.
50. Khan, K.N., Venturini, C.M., Bunch, R.T., Brassard, J.A., Koki, A.T., Morris, D.L., Trump, B.F. et al. Interspecies differences in renal localization of cyclooxygenase isoforms, implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol. Pathol. 1998, 26, 612-620.
51. Hao, C.M., Yull, F., Blackwell, T., Komhoff, M., Davis, L.S., Breyer, M.D. Dehydration activates an NF-kappaB-driven, COX2-dependent survival mechanism in renal medullary interstitial cells. J. Clin. Invest. 2000, 106, 973-982.
52. Yang, T., Singh, I., Pham, H., Sun, D., Smart, A., Schuermann, J.B., Briggs, J.P. Regulation of cyclooxygenase expression in the kidney by dietary salt intake. Am. J. Physiol. 1998, 274, F481-489.
53. Harris, R.C. Cyclooxygenase-2 in the kidney. J. Am. Soc. Nephrol. 2000, 11, 2387-2394.
54. Whelton, A., Hamilton, C.W. Nonsteroidal anti-inflammatory drugs, effects on kidney function. J. Clin. Pharmacol. 1991, 31, 588-598.
55. Swan, S.K., Rudy, D.W., Lasseter, K.C., Ryan, C.F., Buechel. K.L., Lambrecht, L.J., Pinto, M.B. et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann. Intern. Med. 2000, 133, 1-9.
56. Whelton, A., Brater, D.C., Sica, D., Verburg, K.M., Drower, E.J., Geis, G.S. Effects of celecoxib and naproxen on renal function in chronic renal insufficiency patients. J. Am. Soc. Nephrol. 1999, 10, 92A.
57. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin. Exp. Rheumatol. 2001, 19, S15-22.
58. Jolobe, O.M. Nephrotoxicity in the elderly due to co-prescription of ACE inhibitors and NSAIDs. J. R. Soc. Med. 2001, 94, 657-658.
59. Adhiyaman, V., Asghar, M., Oke, A., White, A.D., Shah, I.U. Nephrotoxicity in the elderly due to co-prescription of angiotensin converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J. R. Soc. Med. 2001, 94, 512-514.
60. Chow, K.M., Szeto, C.C., Li, P., Lai, F.M. Acute interstitial nephritis and COX-2 inhibition. Hosp. Med. 2003, 64, 429.
61. Alim, N., Peterson, L, Zimmerman, S.W., Updike, S. Rofecoxib-induced acute interstitial nephritis. Am. J. Kidney Dis. 2003, 41, 720-721.
62. Rocha, J.L., Fernandez-Alonso, J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib. Lancet 2001, 357, 1946-1947.
63. Alper, A.B., Jr., Meleg-Smith, S., Krane, N.K. Nephrotic syndrome and interstitial nephritis associated with celecoxib. Am. J. Kidney Dis. 2002, 40, 1086-1090.
64. Henao, J., Hisamuddin, I., Nzerue, C.M., Vasandani, G., Hewan-Lowe, K. Celecoxib-induced acute interstitial nephritis. Am. J. Kidney Dis. 2002, 39, 1313-1317.
65. Morgenstern, S.J., Bruns, F.J., Fraley, D.S., Kirsch, M., Borochovitz, D. Ibuprofen-associated lipoid nephrosis without interstitial nephritis. Am. J. Kidney Dis. 1989, 14, 50-52.
66. Markowitz G.S., Falkowitz, D.C., Isom, R., Zaki, M., Imaizumi, S., Appel, G.B., D'Agati, V.D. Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxib. Clin. Nephrol. 2003, 59, 137-142.
67. Rossat, J., Maillard, M., Nussberger, J., Brunner, H.R., Burnier, M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin. Pharmacol. Ther. 1999, 66, 76-84.
68. Whelton, A., Schulman, G., Wallemark, C., Drower, E.J., Isakson, P.C., Verburg, K.M., Geis, G.S. Effects of celecoxib and naproxen on renal function in the elderly. Arch. Intern. Med. 2000, 160, 1465-1470.
69. Whelton, A., Fort, J.G., Puma, J.A., Normandin, D., Bello, A.E., Verburg, K.M. Cyclooxygenase-2-specific inhibitors and cardiorenal function, a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am. J. Ther. 2001, 8, 85-95.
70. Pope, J.E., Anderson, J.J., Felson, D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch. Intern. Med. 1993, 153, 477-484.
71. Johnson, A.G., Nguyen, T.V., Day, R.O. Do nonsteroidal antiinflammatory drugs affect blood pressure? A meta-analysis. Ann. Intern. Med. 1994, 121, 289-300.
72. Johnson, A.G., Nguyen, T.V., Owe-Young, R., Williamson, D.J., Day, R.O. Potential mechanisms by which nonsteroidal antiinflammatory drugs elevate blood pressure, the role of endothelin-1. J. Hum. Hypertens. 1996, 10, 257-261.
73. Whelton, A., White, W.B., Bello, A.E., Puma, J.A., Fort, J.G. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol. 2002, 90, 959-963.
74. Schwartz, J.I., Vandormael, K., Malice, M.P., Kalyani, R.N., Lasseter, KC, Holmes GB, Gertz BJ, et al. Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin. Pharmacol. Ther. 2002, 72, 50-61.
75. Clive, D.M., Stoff, J.S. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1984, 310, 563-572.
76. Perazella, M.A. Drug-induced hyperkalemia, old culprits and new offenders. Am. J. Med. 2000, 109, 307-314.
77. Kurata, C., Uehara, A., Sugi, T., Yamazaki, K. Syncope caused by nonsteroidal anti-inflammatory drugs and angiotensin-converting enzyme inhibitors. Jpn. Circ. J. 1999, 63, 1002-1003.